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Background
One of the major challenges in allogeneic stem cell transplantation is to find a balance between
the harmful induction of graft-versus-host disease and the beneficial graft-versus-leukemia and
pathogen-specific immune responses. Adoptive transfer of in-vitro generated donor T cells with
specific anti-leukemic or pathogen-specific activity may be effective. However, in many cases
this requires the in-vitro priming and expansion of antigen-specific precursor T cells from the
naïve donor T-cell repertoire. 
Design and Methods
Antigen-specific CD8 T cells were generated by co-culture of CD45RO-depleted, regulatory T
cell-depleted donor peripheral blood mononuclear cells with autologous peptide-loaded den-
dritic cells, followed by two re-stimulations with peptide-loaded autologous monocytes.
Responding T cells were isolated based on CD137 expression and further purified using pep-
tide/major histocompatibility complex tetramers.
Results
Using this method we were able to reproducibly generate functionally high avidity T cells
directed against multiple viral antigens and minor histocompatibility antigens from the naïve
T-cell repertoire of seronegative, minor histocompatibility antigen-negative donors.
Furthermore, we demonstrated that reduction of the regulatory T-cell frequency by depletion
of CD45RO+ responder cells resulted in improved priming and expansion of antigen-specific
precursor T cells.
Conclusions
In conclusion, we present a robust method for the in-vitro induction and isolation of antigen-
specific T cells from the naïve repertoire. We demonstrate that the likelihood of successful gen-
eration of primary immune responses is determined by a delicate balance between the numbers
of antigen-specific precursor T cells and the numbers and activation state of regulatory T cells
locally at the site of priming of the immune response.
Key words: primary immune responses, regulatory T cells, CMV, minor histocompatibility
anti gens, immunotherapy.
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Introduction
Allogeneic hematopoietic stem cell transplantation (SCT)
is commonly used in the treatment of patients with hema-
tologic malignancies.1 Graft-versus-host disease is the main
complication after transplantation, and T-cell depletion of
the stem cell graft results in a significant reduction of the
incidence of acute graft-versus-host disease. However, since
donor T cells are also the main effectors of the beneficial
graft-versus-leukemia effect after allogeneic SCT, additional
strategies are necessary to support this effect.2,3 Moreover,
pathogen-specific T cells are necessary for adequate protec-
tion of patients against viral and fungal infections.4 Indeed,
infections by human cytomegalovirus (CMV) are a major
cause of morbidity and mortality after T-cell-depleted allo-
geneic SCT.5,6 Ultimately, immunological reconstitution of
T cells derived from the hematopoietic system of donor ori-
gin will be achieved, but it may take more than a year for a
full T-cell repertoire to be formed. In addition, donor T cells
maturing from the stem cell graft are educated in the
patient’s environment, leading to the induction of patient-
specific tolerance, thereby limiting these cells’ potential
anti-leukemic activity. This warrants the exploration of
strategies using donor-derived T cells to supply an adequate
graft-versus-leukemia effect and anti-viral immunity in the
first year after allogeneic SCT. 
Application of unmodified donor lymphocyte infusion
after allogeneic SCT has been demonstrated to result in
graft-versus-leukemia responses and transfer of protective
immunity against CMV, Epstein-Barr virus (EBV) and other
pathogens but may also induce severe graft-versus-host dis-
ease, even at low T-cell doses.7-9 In-vitro induction and selec-
tion of donor T cells with specific anti-leukemic or
pathogen-specific activity may be an attractive strategy to
increase both the specificity and effectiveness of adoptive
transfer of donor T cells, allowing safe application in
immunocompromised patients after allogeneic SCT.
Different strategies have been developed to purify specific
T-cell populations, either based on their specific prolifera-
tion, cytotoxicity, and/or cytokine production after in-vitro
stimulation with the relevant antigen(s) or by direct isola-
tion based on their T-cell receptor (TCR) specificity using
specific peptide/MHC multimers.10-19 Indeed, adoptive
transfer to patients within the first months after transplant
of virus-specific memory T cells isolated from seropositive
donors has been reported to be safe and effective.10,13,16,20
However, if no specific immunological memory response
against the target antigens is present in the donors, the
induction of a primary immune response is required, for
instance to isolate CMV-specific T cells from CMV-seroneg-
ative donors. In general, donor T cells targeting antigens
that are expressed on the (malignant) hematopoietic cells of
the patient, e.g. minor histocompatibility antigens (mHag),
also have to be isolated from the naïve T-cell repertoire.
Because of the very low frequencies of antigen-specific pre-
cursor T cells (Tprec), enrichment of antigen-specific T cells
from primary immune responses to be used for adoptive
transfer requires alternative strategies. Although successful
in-vitro induction and isolation of antigen-specific T cells
from primary immune responses have been reported,21-25
the large number of variables determining the likelihood of
successful induction of primary immune responses has
hampered the reproducible production of enriched popula-
tions of antigen-specific T cells for adoptive transfer. Several
factors may responsible for this variability, including the
very low frequencies of antigen-specific Tprec in the naïve
donor T-cell repertoire, disturbance or overgrowth caused
by off-target bystander activation of neighboring cells, an
inappropriate cytokine milieu, inappropriate antigen pres-
entation, or the active inhibition of the priming of antigen-
specific Tprec by regulatory T cells (Treg).
In this paper we describe the in-vitro induction of antigen-
specific primary immune responses and present a strategy
resulting in the reproducible induction and expansion of
antigen-specific T cells from the naïve donor T-cell com-
partment. 
Design and Methods
Donors
Peripheral blood from healthy donors was harvested after
informed consent. Peripheral blood mononuclear cells (PBMC)
were isolated by Ficoll density separation and cryopreserved for
further use. Donors positively typed for HLA-A*0101, A*0201,
A*2402, B*0702, and/or B*0801 by high resolution genomic DNA
typing and with a negative serostatus for CMV were selected. 
Selection of cell populations
The selection of cell populations is described in the Online
Supplementary Appendix.
Analysis of T-cell activation kinetics
To analyze the kinetics of activation of naïve T cells, memory T
cells and Treg, the cells were exposed to either autologous or HLA-
mismatched allogeneic monocyte-derived dendritic cells at a 1:1
ratio, or were polyclonally activated using CD3/CD28 T-cell acti-
vation beads (Dynabeads, Invitrogen, Life Technologies, Breda,
The Netherlands) at a 10:1 cell to bead ratio in Iscove’s modified
Dulbecco’s medium (IMDM) containing 10% human serum. T-cell
activation was measured by flow cytometric analysis of the
expression of T-cell activation markers, as described below, on
days 1, 2 and 3 after stimulation.
Peptides and tetramers
Information on the specific peptides and the generation of
tetramers is provided in the Online Supplementary Appendix.
Activation and enrichment of antigen-specific T cells
Autologous monocyte-derived antigen-presenting cells (APC)
were exogenously loaded for 2 h at 37°C with 1 μM of each rele-
vant peptide, followed by three washing steps. CD14- or
CD14/CD45RO-depleted responder cells were seeded at a concen-
tration of 1¥106 cells/mL and co-cultured for 10 days with irradiat-
ed (25 Gy) peptide-loaded APC at a 10:1 responder to stimulator
(R:S) ratio in IMDM containing 10% prescreened human serum
and supplemented with 5 ng/mL human interleukin (IL)-7
(Biosource/Invitrogen, Breda, The Netherlands). In a selected num-
ber of experiments 5 ng/mL IL-15 and/or IL-21 (Biosource) were
also added. On day 10 of the immune response the antigen-specific
T cells were specifically re-stimulated with irradiated (25 Gy) pep-
tide-loaded (1 μM) autologous monocytes at a 10:1 R:S ratio. On
day 20 of the immune response a second re-stimulation step with
irradiated (25 Gy) peptide-loaded (1 µM) autologous monocytes
was performed (R:S ratio, 10:1), followed by isolation of the
responding cells based on their induced surface expression of
CD137. Cells were labeled with allophycocyanin-conjugated
CD137 antibodies (clone 4B4-1, BD biosciences, Breda, The
Netherlands) for 30 min at 4°C, washed and isolated by magnetic
bead separation using anti-allophycocyanin beads according to the
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manufacturer’s instructions (Miltenyi Biotec). Post-isolation expan-
sion was induced using an allogeneic feeder mixture consisting of
culture medium, 5 x irradiated allogeneic feeder cells, 0.5 x irradi-
ated allogeneic EBV-induced lymphoblastoid cell lines (EBV-LCL),
100 IU/mL IL-2, and 800 ng/mL phytohemagglutinin (PHA, Murex
Biotech Limited, Dartfort, UK), or in a selected number of experi-
ments using a feeder mixture consisting of culture medium, 5 x
autologous feeder cells (CD14-negative PBMC fraction), 5 ng/mL
IL-7, 5 ng/mL IL-15, and 0.2 x CD3/CD28 Dynabeads ClinEx
(Invitrogen, Life Technologies). The purity of the isolated cell pop-
ulations was determined by flow cytometric analysis of the fre-
quencies of T cells stained with the relevant tetramers on day 7-10
after re-stimulation. For further enrichment steps, the antigen-spe-
cific cells were stained with phycoerythin (PE)- or allophyco-
cyanin-labeled tetramers for 30 min at 4°C, followed by magnetic
bead isolation using fluorochrome-specific magnetic beads
(Miltenyi Biotec) and, 10-14 days post-isolation expansion, using
an allogeneic feeder mixture. 
Analysis of cytotoxicity and cytokine production
The cytotoxic capacity of the isolated antigen-specific T cells
was determined in standard 6 h 51Cr release assays.26 As target cells,
autologous monocytes or EBV-LCL exogenously loaded with dif-
ferent concentrations (1 pM to 1 μM) of the relevant peptides were
used. To test the functional activity of the T cells against target cells
presenting endogenously processed antigen, we used EBV-LCL
that were incubated overnight at 37°C with protein-spanning over-
lapping peptide pools (CMV/pp65 and CMV/IE1, 1 μM) or recom-
binant CMV/pp65 protein (Miltenyi Biotec), or EBV-LCL trans-
duced with a retroviral vector containing a CMV/pp65 expression
construct27 as target cells. Target cells were incubated with effector
cells at an E:T ratio of 5:1. In some experiments, CMV-infected
human fibroblasts were used as target cells. For this purpose,
MRC-5 human fetal lung fibroblasts (American Type Culture
Collection; ATCC; Wessel, Germany) were infected in vitro with
the AD 169 human herpes virus 5/CMV strain (ATCC).
For analysis of interferon-γ production, 5,000 T cells were co-cul-
tured with 30,000 stimulator cells. After 24 h, supernatants were
harvested and the concentration of interferon-γ was measured by
an enzyme-linked immunsorbent assay (Sanquin Reagents,
Amsterdam, The Netherlands).
Flow cytometry analysis and
proliferation/inhibition assays
Information on the methods used for flow cytometry analysis
and the antibodies employed is provided in the Online
Supplementary Appendix. Details of the assays used for the analysis
of T-cell proliferation and Treg inhibition are also given in the
Online Supplementary Appendix.
Statistical analysis
The statistical evaluation of the data was performed using the
paired Student's t test.
Results
In-vitro priming of primary immune responses 
by peripheral blood mononuclear cells in the presence of
various cytokines
To induce primary immune responses in vitro against
CMV and/or mHag, PBMC from CMV-seronegative
healthy donors were exposed to autologous monocyte-
derived dendritic cells, exogenously loaded with mixtures
of relevant 9-11-mer peptides (2-8 per response) derived
from the CMV proteins CMV/pp50, CMV/pp65 and imme-
diate early antigen 1 (CMV/IE1), and the mHag LB-ADIR-
1F, LB-ECGF-1H, HA-1 and ACC1y binding to HLA-
A*0101, A*0201, A*2402, B*0702 or B*0801, depending on
the HLA typing of the responder cells, followed by specific
re-stimulation steps. In pilot studies, we attempted to
induce CMV-specific and/or mHag-specific CD8+ T cells
from ten CMV-seronegative, mHag-negative donors using
this protocol in the presence of IL-7, IL-15 and IL-2. This did
not lead to the induction of detectable populations of CD8+
T cells recognizing the targeted antigens as measured by
tetramers. In contrast, we observed off-target expansion of
CD8+ T cells, CD4+ T cells, NK cells and/or γδ T cells. To
determine whether the specific cytokine milieu was
responsible for this off-target expansion, we tested various
combinations of cytokines in the stimulation protocol in the
presence or absence of exogenous antigen. Since IL-7 has
been described to be responsible for the in-vivomaintenance
and expansion of the naïve T-cell pool,28 IL-7 was used in all
cultures. Addition of IL-2 did not improve the generation of
CMV-specific T cells in our system and also did not influ-
ence the composition of the cultures (data not shown). Both
in the absence and presence of specific peptides loaded on
the APC, the addition of IL-21 resulted in significant off-tar-
get expansion of γδ T cells (10.1-fold increase, n=6), and the
addition of IL-15 resulted in undesired expansion of both
NK cells and γδ T cells (22.3- and 4.4-fold increase, respec-
tively, n=6). Both cytokines also induced off-target prolifer-
ation of normal abTCR+ T cells (1.3- and 2.1-fold increase
for IL-21 and IL-15, respectively, n=6), resulting in overall
increased numbers of CD4 and CD8+ T cells. Therefore, in
order to minimize off-target expansion and to avoid the risk
of favoring IL-2-mediated activation of Treg, IL-7 was the
only exogenous cytokine added to the cultures.
CD45RO depletion resulted in combined depletion
of memory and regulatory T cells allowing in-vitro
generation of primary immune responses
Since primary immune responses are derived from the
naïve T-cell repertoire, depletion of CD45RO+ memory T
cells may limit off-target bystander proliferation, and will
result in at least a 2-fold increase in the frequency of naïve
Tprec. Moreover, since the majority of naturally occurring
CD4+/FoxP3+ Treg are CD45RO+,29-32 depletion of
CD45RO+ cells from the responder PBMC population
may also result in depletion of most Treg. We investigat-
ed the frequencies of CD4+/CD25+/FoxP3+ Treg and
CD45RA+/CD27+/CD62L+ naïve T cells before and after
CD45RO depletion. CD45RO depletion resulted in a
decrease of Treg from 0.2-4.5% to only 0-0.1% (n=20).
Although CD45RA+/FoxP3+ Treg with inhibitory poten-
tial have been described,33,34 their numerical contribution
to the total number of circulating Treg is low, resulting in
almost complete removal of Treg from the responder cell
population by CD45RO depletion. The frequency of
naïve T cells increased after CD45RO depletion, such that
these cells comprised 85-99% of the responder T-cell pop-
ulation, depending on the frequency of the contaminating
CD45RA+/CD27– late stage effector T cells. Using CD45RO
depleted donor PBMC as responder cells and monocyte-
derived dendritic cells loaded with multiple CMV- and
mHag-specific peptides as stimulator cells, we were able to
successfully activate and expand antigen-specific T cells as
demonstrated by tetramer staining. Figure 1 shows tetramer
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stains of representative immune responses for three individ-
ual donors. As shown in the upper dot plot in Figure 1A, no
tetramer-positive cells could be identified in the naïve donor
repertoire prior to the induction of the immune response.
This observation was made for all responder cell popula-
tions within this cohort. In most responses, the number of
tetramer-positive cells was still below the detection limit 10
and 20 days after initial priming. On day 20 of the immune
response, a second re-stimulation with peptide-loaded
autologous monocytes was performed and activated T cells
were isolated based on their expression of the activation
marker CD137 after 24 h, resulting in enrichment of virus-
specific T cells (Figure 1A) and mHag-specific T cells (Figure
1B and C) with various specificities. Figure 1 shows repre-
sentative examples for different specificities enriched with-
in different immune responses. These tetramer-positive T-
cell populations could be further purified using
peptide/MHC multimers (data not shown). 
Influence of CD45RO-positive regulatory T cells 
on the generation of primary immune responses
To investigate whether not only depletion of memory T
cells but also depletion of Treg by CD45RO depletion of the
responder T-cell population was relevant for the improve-
ment of the procedure, we restored the initial frequencies of
Treg prior to CD45RO depletion by adding back MACS-
purified CD4+/CD25high/CD45RO+ Treg to the
CD14/CD45RO-depleted naïve responder population prior
to the induction of the immune response. The percentages
of FoxP3+ cells within these isolated cell populations ranged
from 40-76%. As illustrated by a representative example in
Figure 2, Treg add-back strongly inhibited the induction of
the immune response, demonstrated by the decreased fre-
quencies of tetramer-positive cells (1.69%±1.82 without
Treg add-back versus 0.154%±0.25 with Treg add-back,
P<0.05, n=10). These differences were similarly reflected in
the absolute numbers of tetramer-positive cells that were
generated (4.5-fold decrease, P<0.05, n=10). In conclusion,
In vitro generation of antigen-specific T cells from the naïve compartment
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Figure 1. In-vitro generation of
virus-specific and mHag-specific
T cells from a primary immune
response PBMC from CMV-
seronegative, mHag-negative
healthy donors were depleted of
CD45RO+ cells by magnetic bead
separation prior to co-culture
with autologous monocyte-
derived dendritic cells exoge-
nously loaded with a mixture (2-
8 per response) of CMV-derived
and mHag-derived 9-11 mer pep-
tides binding in HLA-A*0101,
A*0201, A*2402, B*0702 or
B*0801. Representative exam-
ples of tetramer stains after
CD137 enrichment of respond-
ing cells on day 21 of the
immune response are shown.
The upper dot plot (pre) shows
the absence of tetramer-positive
cells prior to the induction of the
immune response. The lower
panels of dot plots (after) show
the presence of CMV-specific T
cells with different specificities in
donor 1 (A) and mHag-specific T
cells in donors 2 (B) and 3 (C)
after in-vitro activation and
enrichment. 
Figure 2. Dampening of the in-vitro induction of anti-
gen-specific primary immune responses by CD45RO+
regulatory T cells. Primary immune responses against
multiple HLA-A*0101, A*0201, B*0702 or B*0801-
binding CMV peptides were induced using CD45RO-
negative naïve T cells from CMV-seronegative donors
as responder cells and peptide-loaded autologous den-
dritic cells as stimulator cells (n=4). The effect of
restoring the frequency of Treg by adding back purified
CD4+/CD25high/CD45RO+ Treg at the onset of the
immune response was analyzed. The presence of
CMV-specific tetramer-positive T cells on day 30 of the
immune response after in-vitro induction, expansion
and CD137 enrichment in the absence (upper panel)
or presence (lower panel) of Treg are shown for one
immune response as a representative example. 
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not only enrichment of naïve Tprec, but also the depletion
of CD45RO+ Treg contributed to the increased robustness
of the procedure. 
Since the frequencies of Treg in unseparated PBMC are
approximately 100- to 1000-fold higher than the frequen-
cies of Tprec specific for antigens targeted in a primary
immune response, this may shift the balance towards neg-
ative regulation, whereas after CD45RO depletion the bal-
ance will change in favor of priming of the Tprec, despite
the remaining minimal frequencies of CD45RO-negative
naïve Treg. We hypothesized that if both the Treg and the
antigen-specific Tprec were activated by the mature den-
dritic cells, this would explain the delicate balance between
induction and regulation. As shown in Online Supplementary
Figure S1, naturally occurring CD4+/CD25high/FoxP3+ Treg in
primary donor PBMC were not activated (panel A), but 24
h after exposure to autologous APC up-regulation of the
activation markers GITR and CD137 and down-regulation
of the naïve T-cell marker CD62L were observed (panel B).
In addition, the activation of Treg was accompanied by a 3-
fold increase in intensity of FoxP3 expression (average MFI
192±12 and 562±25, respectively, n=3). These results indi-
cate that not only the relative numbers of Treg and Tprec,
but also the kinetics of their activation may determine the
balance between inhibition by Treg and priming of Tprec.
Since the frequencies of antigen-specific Tprec are too low
to analyze the activation kinetics after antigen-specific stim-
ulation, we used a polyclonal stimulation via the TCR by
CD3/CD28 stimulation beads and analyzed the kinetics of
activation of conventional T cells and Treg. As shown by a
representative example in Figure 3, 1 day after stimulation
with CD3/CD28 beads, uniform up-regulation of the acti-
vation markers CD69, GITR and CD137 and down-regula-
tion of CD62L was seen in the FoxP3+ Treg population,
whereas even after this strong activation signal only part of
the conventional T cells was activated (Figure 3B). Figure 3C
illustrates the rapid and uniform activation of Treg already
within the first day after stimulation, whereas both
CD45RO– naïve T cells and CD45RO+ memory T cells
showed more delayed and partial activation within the first
days after polyclonal activation via CD3/CD28 stimulation
(n=6, P<0.01).
Next, we investigated whether the activation of Treg
induced by exposure to autologous APC or polyclonal acti-
vation via their TCR increased their inhibitory potential. As
shown in Online Supplementary Figure S2, freshly isolated
Treg inhibited CD3/28-induced proliferation of naïve Tprec
only when they had a numerical advantage (Treg frequen-
cies >50%) (white circles). Activation by exposure of the
Treg to autologous APC increased their inhibitory potential,
reflected by inhibition of Tprec proliferation at lower Treg
frequencies (gray circles, P=0.03). More vigorous TCR-
mediated activation of Treg mimicked by CD3/CD28
cross-linking further increased their inhibitory potential
I. Jedema et al.
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Figure 3. Differential activation kinetics
of regulatory and conventional T cells.
The activation state of conventional T
cells and FoxP3+ Treg from a healthy
donor under steady state conditions (A)
and 24 h after polyclonal stimulation
with CD3/28 beads (B) was determined
by flow cytometric analysis of co-expres-
sion of CD62L, CD69, GITR and CD137.
Treg were identified by FoxP3 staining.
Panel C shows the kinetics of expression
of these markers on days 1, 2, and 3
after CD3/28 stimulation specifically on
Treg, CD45RA+ naïve T cells, and
CD45RO+ memory T cells (n=6).
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(black circles, P<0.01). In conclusion, depletion of Treg pre-
vents the local inhibition of activation of Tprec locally at the
site of the APC, increasing the capacity of the dendritic cells
to induce a primary immune response.
Isolation of high avidity cytomegalovirus-specific 
and minor histocompatibility antigen-specific 
T cells from the naïve T-cell compartment 
of cytomegalovirsu-seronegative, minor 
histocompatibility antigen-negative donors
The reproducibility of our method to induce primary
immune responses against different CMV-derived epitopes
was tested in a cohort of 36 CMV-seronegative healthy
donors. CMV-specific T cells could be detected after CD137
enrichment in only 55% of the immune responses started
with less than 25¥106 CD45RO depleted donor PBMC
(n=14). When the starting population consisted of more
than 25¥106 T cells (n=22), 96% of the attempts were suc-
cessful in generating at least one CMV specificity, illustrat-
ing that the frequencies of Tprec specific for the targeted
CMV antigens within the naïve donor T cell repertoire were
low.
The results from these 22 inductions starting with more
than 25¥106 CD45RO-depleted donor PBMC are summa-
rized in Figure 4A. The listed individual epitopes could be
targeted in 13-22 separate immune responses, depending on
the HLA typing of the donors, and the percentages of suc-
cessful inductions per specificity ranged from 13% (2/15) to
73% (16/22). Induction of an immune response was consid-
ered successful when a population of tetramer-positive
CD8+ T cells consisting of more than 0.5% of the total T-cell
population could be detected. The most frequent inductions
of T cells were directed against four CMV/pp65 and
CMV/IE1-derived epitopes presented in HLA-A*0101,
B*0702 and B*0801. To investigate whether the immun-
odominance of HLA-B*0702 epitopes impaired the proper
induction of an HLA-A*0201-restricted response, we inves-
tigated the co-expression of HLA-B*0702 in the donors
capable or incapable of mounting an HLA-A*0201-
restricted immune response in our cohort finding that this
was not different between the groups (50% in the non-
responders and 48% in the responders). After CD137-based
enrichment on day 21 of the immune responses, the fre-
quencies of tetramer-positive cells ranged from 0.1%-21%
(median, 1.9%). The antigen-specific T cells displayed
oligoclonal TCR Vb usage (data not shown). Due to the low
level of exogenously added cytokines, no massive increases
in total cell numbers were observed during the induction
phase of the immune responses, resulting in a median 2.25-
fold (range, 0.35-4.9) increase in total cell numbers on day
20 of the immune responses. The frequencies of CD137+ T
cells on day 21 after the second specific re-stimulation
ranged from 0.1-3.2% (median, 1.6%). In absolute num-
bers, this translates into the isolation of 350 - 34¥106
tetramer-positive cells from 1¥106 responder cells using this
procedure. This again illustrates the initial low frequencies
of antigen-specific precursor cells within the total naïve
responder cell populations. 
To further illustrate that the Tprec frequency rather than
the nature of the targeted antigen determines the success of
in-vitro generation of a primary immune response, we gen-
erated immune responses against the HLA-A*0201-binding
mHag HA-1 (n=4), LB-ADIR-1F (n=2), the HLA-B*0702-
binding mHag LB-ECGF-1H (n=5), and the HLA-A*2402-
binding mHag ACC1Y (n=1) from mHag-negative donors.
As shown in Figure 4B, in more than 50% of the responses
we were able to isolate tetramer-positive cells against these
mHag.
To investigate whether the tetramer-positive T cells were
high avidity T cells, we tested their capacity to recognize
and kill target cells expressing endogenously processed anti-
gen. Figure 4C shows a representative example of this
analysis for a population of CMV/pp65-TPR-B*0702-
specific T cells (98% tetramer-positive). The in-vitro generat-
ed CMV-specific T cells showed efficient cytotoxic activity
in a conventional 6 h 51Cr release assay against HLA-B*0702
positive EBV-LCL exogenously loaded with the 10-mer
peptide, even at nanomolar concentrations. Moreover, they
also recognized and lysed EBV-LCL presenting the relevant
peptide after endogenous processing of either synthetic
CMV/pp65 spanning overlapping peptides (pepmix),
recombinant CMV/pp65 protein, or CMV/pp65 protein
introduced via retroviral transduction. CMV-infected
human fibroblasts were also killed by the CMV/pp65-spe-
cific T cells to levels comparable to those obtained with
alloreactive T-cell clones in 6 h conventional 51Cr release
assays, resulting in 25-55% lysis (E:T ratio, 10:1, n=3).
Figure 4D shows the reactivity of three mHag-specific T-cell
clones against mHag-positive EBV-LCL, demonstrating
their potent functional avidity. Overall, the cytotoxicity
analyses performed with the in-vitro generated CMV-specif-
ic and mHag-specific T-cell populations showed that the
isolated populations of tetramer-positive cells were capable
of recognizing both exogenously loaded, as well as
processed antigen presented by monocytes or EBV-LCL.
This cytotoxic activity coincided with down-regulation of
their TCR and production of interferon-γ (data not shown). 
Isolated tetramer-positive T cells always expressed
CD45RO and CD27, but the majority (90%) lacked expres-
sion of CCR-7 and CD28, illustrating their effector memory
phenotype. Tetramer-positive populations could be further
purified to relatively pure populations (containing >80%
tetramer-positive cells) by one or two sequential rounds of
enrichment using tetramer isolation (Figure 4E-F), thereby
confirming the specificity of the low frequency tetramer
staining directly after CD137 enrichment. Routinely, 5- to
139-fold (median, 56-fold) expansion of the isolated T cells
was observed in the 10-14 days between the isolations/re-
stimulations. This very marked capacity for in-vitro expan-
sion in the bulk cultures and also after clonal isolation
allowed the generation of large numbers of antigen-specific
T cells using this procedure. Both the virus-specific T-cell
clones as well as the mHag-specific T-cell clones could be
maintained in culture for months and retained their prolif-
erative and functional capacity after bi-weekly re-stimula-
tions. We did not observe differences in the phenotype, fre-
quencies or proliferative potential between the mHag-spe-
cific T cells and the virus-specific T cells isolated from the
naïve donor repertoire after in-vitro stimulation.
Discussion
In this study we developed a robust method for the in-
vitro generation of functional antigen-specific CD8+ T cells
from the naïve donor T-cell repertoire. In this strategy,
donor PBMC were depleted of CD45RO+ memory T cells
and Treg and co-cultured with autologous monocyte-
derived dendritic cells exogenously loaded with a mixture
of relevant 9-11 mer peptides. At days 10 and 20 of the
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immune response the T cells were specifically re-stimulated
with peptide-loaded autologous monocytes, and 24 hours
after the second re-stimulation the responding T cells could
be enriched based on their induced surface expression of
the activation marker CD137. Further purification of the
antigen-specific T cells was performed using specific pep-
tide/MHC tetramers. Using this method we were able to
generate functionally highly avid T cells directed against
viral antigens as well as T cells directed against mHag, illus-
trating the broad applicability of this approach.
Although several strategies for the in-vitro induction of
primary immune responses against defined antigens have
been proposed previously,21-25 the number of variables
underlying the reproducibility of these methods limits their
large scale clinical application. In this study, we investigated
individual factors that together determined the likelihood of
successful priming and enrichment of antigen-specific naïve
Tprec. We demonstrated that depletion of CD45RO-
expressing cells from the donor PBMC prior to induction of
the immune response significantly increased the capacity to
reproducibly induce primary immune responses, and fur-
ther enrich the antigen-specific T cells. Our study explains
the mechanisms underlying the improved results after
CD45RO depletion. As also previously indicated by oth-
ers,22,23 depletion of CD45RO+ cells resulted in an increment
of the frequencies of antigen-specific naïve Tprec by deple-
tion of the memory T-cell pool. We, however, hypothe-
sized that the resulting 2-fold increment in Tprec frequency
was unlikely to be the sole cause of the major increase in
efficiency of the procedure. The cytokine milieu caused by
the cytokines exogenously added to the in-vitro cultures
strongly influenced the composition of the cell cultures.
Although the addition of IL-15 and IL-21 has been described
to be beneficial for the expansion of antigen-specific T
cells,23,35,36 we observed massive off-target proliferation of
bystander T cells and NK cells upon addition of these
cytokines, hampering the efficient enrichment of the target-
ed T-cell populations. IL-7 as a single exogenous cytokine
I. Jedema et al.
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Figure 4. Reproducible in vitro induction of functionally active virus-specific
and mHag-specific CD8+ T cells from seronegative mHag-negative donors.
(A) In a cohort of 22 CMV-seronegative donors primary immune responses
were induced by in-vitro stimulation of more than 25x106 CD45RO-negative
PBMC with autologous monocyte-derived APC exogenously loaded with a
mixture of CMV-derived peptides binding in HLA-A*0101, A*0201, B*0702
or B*0801. The listed individual epitopes were targeted in 13-22 separate
immune responses depending on the HLA typing of the respective donor
(indicated by the numbers above the bars). 
The immune response was considered successful when a population of tetramer-positive cells consisting of more than 0.5% of the PBMC
population was detected on day 30 of the immune response after in-vitro priming, expansion and CD137 enrichment. (B) In a smaller cohort
of six mHag-negative donors immune responses were induced against the HLA-A*0201-restricted mHag HA-1 (n=4) and LB-ADIR-1F (n=2),
the HLA-A*2402-restricted mHag ACC1Y (n=1), and the HLA-B*0702-restricted mHag LB-ECGF-1H (n=5). (C) The functional activity of the
bulk populations of in-vitro generated CMV-specific and mHag-specific T cells was tested in conventional 6 h 51Cr release assays using as
target cell monocytes or EBV-LCL exogenously loaded with the respective 9- to 11-mer peptides, or presenting processed antigen. A repre-
sentative example is shown for a bulk population of in-vitro generated HLA-B7-restricted CMV/pp65 (TPR)-specific T cells (98% tetramer-
positive). HLA-B7+ EBV-LCL loaded with different concentrations (1 nM - 1 µM) of the specific 10-mer peptide, or presenting the relevant pep-
tide after endogenous processing of either synthetic CMV/pp65 spanning overlapping peptides (pepmix), recombinant CMV/pp65 protein,
or CMV/pp65 protein induced via retroviral transduction were used as target cells. T cells were added at am E:T ratio of 5:1. (D) The func-
tional activity is shown for three mHag-specific T cells clones [HA-1 (□), ACC1Y (■), and LB-ECGF-1H (■)] isolated on day 20 after in-vitro stim-
ulation from the naïve T-cell compartment using single-cell sorting based on tetramer expression. Cytotoxicity against mHag-negative and
mHag-positive EBV-LCL expressing the relevant HLA restriction molecules (e.g. HLA-A*0201, -A*2402, and -B*0702) was tested in a con-
ventional 6 h 51Cr release assay (E:T ratio 5:1). (E-F) Tetramer-positive cell populations were further purified after initial CD137 enrichment
using tetramer staining and magnetic bead selection. Depending on the initial frequencies of tetramer-positive cells, one or two sequential
steps of tetramer enrichment followed by 10-day in-vitro expansion periods were necessary to obtain relatively pure populations containing
more than 80% of tetramer-positive cells. A representative example of the frequencies of virus-specific T cells (E) and mHag-specific T cells
(F) on day 20 of the immune response, 7 days after CD137 isolation, and 7 days after tetramer enrichment(s) is shown.
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supported the survival of the naïve Tprec sufficiently,28
without inducing massive off-target background prolifera-
tion and circumvented the need for the addition of IL-2 to
the culture. Since naturally occurring Treg capable of
inhibiting the priming of naïve antigen-specific Tprec show
high expression of the IL-2 receptor CD25, but lack expres-
sion of the IL-7 receptor CD127,37-39 the addition of IL-7 but
not IL-2 in our procedure may have favored Tprec priming.
Because most naturally occurring Treg are CD45RO+,29-31
depletion of CD45RO-expressing responder cells resulted
not only in the depletion of memory T cells but also in the
relative depletion of CD4+/CD25high/FoxP3+ Treg. By restor-
ing the initial Treg frequencies by adding back purified
CD4+/CD25high/FoxP3+ Treg to the CD45RO-depleted donor
PBMC prior to the induction of the immune response, we
demonstrated the capacity of the CD45RO+ Treg to damp-
en the proper priming and/or expansion of the antigen-spe-
cific Tprec. In subsequent experiments we demonstrated
that similar to the antigen-specific Tprec, the CD45RO+
Treg were activated by the antigen-presenting dendritic
cells used for the initial stimulation. This activation aug-
mented their capacity to inhibit antigen-specific activation
of Tprec even when they were in a numerical minority.
Moreover, we demonstrated that the kinetics of Treg acti-
vation were faster than the kinetics of activation of the
majority of conventional T cells. Although the absolute
number of Treg within the donor PBMC population is rela-
tively low, the extremely low frequencies of naïve antigen-
specific Tprec40 cause an imbalance in favor of the Treg
locally at the site of priming of the immune response, e.g.
the antigen-presenting dendritic cells. The rapid kinetics of
their activation and the resulting increased capacity to
impair Tprec priming may further explain the remarkable
impact of Treg depletion on the capacity to induce antigen-
specific primary immune responses. In memory T-cell
responses Treg-mediated suppression is less likely to occur
since the frequencies of antigen-specific memory cells may
override the number of Treg and their priming does not
require interaction with professional APC.
Using this procedure, we were able to reproducibly
induce CD8 T cells against multiple viral antigens as well as
mHag only when the responses were initiated from more
than 25¥106 CD45RO-negative donor PBMC, illustrating
that the Tprec frequencies rather than the nature of the tar-
geted antigen determines the likelihood of successful induc-
tion and expansion of the antigen-specific T cells. All isolat-
ed antigen-specific T-cell populations showed a high avidity
reaction pattern, as demonstrated by their capacity to effi-
ciently recognize and lyse target cells presenting endoge-
nously processed antigen. The CD137 enrichment step in
our procedure may further enhance the proliferative and
survival capacity of the antigen-specific T cells due to the
beneficial co-stimulatory signal supplied by cross-linking of
CD137 on the T-cell surface during the isolation proce-
dure.41,42 This procedure may allow the generation of anti-
gen-specific T cells for clinical application. However, since
the frequencies of Tprec against single antigens is low, fur-
ther enrichment and vigorous post-isolation expansion
remain necessary to allow in-vivo infusion of substantial
numbers of specific cells and limited numbers of T cells of
unknown specificity. Depending on frequencies of
tetramer-positive cells in the T-cell population after CD137
enrichment, one or two sequential enrichment steps based
on tetramer isolation were necessary to obtain a T-cell prod-
uct containing more than 80% tetramer-positive cells, suit-
able for clinical application. This would require a 30-40 day
culture period. In the experiments described in this article,
post-isolation expansion was performed using allogeneic
feeder cells and PHA, which is not suitable for the produc-
tion of cells for clinical application. In a selected number of
experiments we demonstrated similar expansion of the cells
using autologous feeder cells, a medium containing IL-7 and
IL-15, and clinical grade CD3/CD28 microbeads (data not
shown), allowing the generation of antigen-specific T cells
from the naïve donor repertoire under Good Manufacturing
Practice conditions. Although this method is still complex
and laborious, these cells may be of great therapeutic
importance in selected patients. A further increment of the
antigen-specific Tprec frequencies by increasing the num-
ber of targeted antigens using a cocktail of multiple peptides
as an ‘in-vitro vaccine’ may further increase the robustness of
the procedure. Since CD137 is expressed on activated CD4
T cells as well,19 the method can also be applied for the iso-
lation of T cells targeting HLA-class II-restricted antigens.
In conclusion, we present a robust method for the in-vitro
induction and isolation of antigen-specific T cells from the
naïve repertoire. We demonstrated that the likelihood of
successful generation of primary immune responses is
determined by a delicate balance between the numbers of
naïve antigen-specific Tprec and the numbers and activa-
tion state of Treg locally at the site of priming of the
immune response. 
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